肝癌发展中FasL及其受体Fas/DcR3的表达分析  

Analysis of FasL and Fas/DcR3 expression in hepatocellular cancer development

作　　者：刘忠臣[1] 罗芳洪[2] 陈彩霞[2] 杨东海[2] 范鑫[2] 程小峰[2] 庄国洪[2] 

机构地区：[1]厦门大学附属中山医院胃肠外科,361004 [2]厦门大学医学院抗癌研究中心,361005

出　　处：《免疫学杂志》2010年第3期242-245,共4页Immunological Journal

基　　金：厦门科技计划项目(3502Z20083008)资助

摘　　要：目的研究小鼠肿瘤发生早期肿瘤坏死因子超家族成员FasL及其受体的表达特点,及其与免疫调节相关分子表达的时空关系,探讨其在诱导肿瘤免疫耐受中的作用。方法建立小鼠实体瘤模型,采用RT-PCR方法检测肿瘤组织中可溶型FasL、Fas及DcR3、TGF-β、IL-10在肿瘤发生不同时相的表达,同时,应用ELISA方法定量检测血清中TGF-β、IL-10的表达。结果在早期的肿瘤组织中,Fas的表达先于DcR3,其后DcR3大量表达,而Fas的表达则下调直至丢失,DcR3、FasL同时表达并上调,TGF-β和IL-10也随肿瘤的表达而上调。TGF-β同DcR3的表达具有空间位置的一致性。FasL、DcR3、TGF-β和IL-10的表达水平同肿瘤的生长呈正相关。结论随着肿瘤不断的生长,肿瘤局部的免疫应答逐渐趋向于负调节,FasL、DcR3在诱导肿瘤免疫耐受的过程中可能发挥着重要作用。To evaluate the role of the tumor necrosis factor （TNF） snpeffamily member FasL and its receptors in immunologic tolerance, we characterized the expression of FasL and its receptors, and their relation with immuuoregulation related cytokines. We built a murine model and measured the expressions of soluble FasL, Fas, DcR3, TGF-β, IL-10in tumor at different phases by using RT-PCR, at the same time we detected the levels of TGF-β and IL-10 in serum by ELISA. At early phases of tumorigenesis, the Fas expression was ahead to DcR3, as time went on, DcR3 expression increased but the expression of Fas was down-regulated. DcR3 and FasL expression up-regulated simultaneously; expression levels of TGF-β and IL-10 were up-regulated with development of tumorigenesis. In addition, the expression levels of FasL, DcR3, TGF-β, and IL-10 were positively related with tumor growth. The results shows that FasL and DcR3 maybe play an important role in inducing immunologic tolerance in tumorigenesis.

关 键 词：FASL DCR3 FAS 肝癌 

分 类 号：R735.7[医药卫生—肿瘤]